May 4, 2017 / 12:45 PM / 4 months ago

BRIEF-Sangamo Therapeutics says special regulatory designations from FDA for 3 clinical programs

May 4 (Reuters) - Sangamo Therapeutics Inc

* Sangamo therapeutics announces special regulatory designations from the fda for three clinical programs

* Sangamo therapeutics inc- rare pediatric disease designation for sb-913 in vivo genome editing treatment for mps ii

* Sangamo therapeutics inc- orphan drug designation for sb-525 cdna gene therapy for hemophilia a

* Sangamo therapeutics inc- fast track designation for sb-fix in vivo genome editing treatment for hemophilia b Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below